<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04985357</url>
  </required_header>
  <id_info>
    <org_study_id>TRV-002</org_study_id>
    <nct_id>NCT04985357</nct_id>
  </id_info>
  <brief_title>Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs</brief_title>
  <official_title>Defining the Clinical Potential of Mass Response as a Biomarker for Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Travera LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>John B. Amos Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Travera LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study, sponsored by Travera LLC in Massachusetts, is to&#xD;
      validate whether the mass response biomarker has potential to predict response of patients to&#xD;
      specific therapies or therapeutic combinations using isolated tumor cells from varying&#xD;
      cancers and biopsy formats. Cohorts include patients with stage III or IV breast cancer,&#xD;
      stage III or IV lung cancer, active AML, and relapsed multiple myeloma. This pilot study will&#xD;
      utilize samples from patients undergoing routine biopsy of their tumor as part of their&#xD;
      clinical care (e.g. for clinical diagnosis, staging, DNA molecular analysis). This study will&#xD;
      involve additional material from the same procedure the patient is already undergoing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>4 months, up to 24 months</time_frame>
    <description>The best overall response to therapy will be captured for correlation with test outcomes. The duration of this best overall response assessment will be 4-months for AML and MM, and 4-months up to 24-months for breast and lung cancer.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Stage III Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Stage III Lung Cancer</condition>
  <condition>Stage IV Lung Cancer</condition>
  <condition>AML</condition>
  <condition>Multiple Myeloma in Relapse</condition>
  <arm_group>
    <arm_group_label>Breast Cancer</arm_group_label>
    <description>Diagnosis of stage III or IV breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lung Cancer</arm_group_label>
    <description>Diagnosis of stage III or IV lung cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute myelogenous leukemia (AML)</arm_group_label>
    <description>Diagnosis of acute myelogenous leukemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Myeloma</arm_group_label>
    <description>Diagnosis of relapsed multiple myeloma</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        General population with cohort matched diagnoses.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy of tumor is clinically indicated as part of SOC&#xD;
&#xD;
          -  Prior to preceding onto therapy for treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to obtain sufficient sample&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Stevens, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Travera LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Kimmerling, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Travera LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Stevens, Ph.D.</last_name>
    <phone>6172999784</phone>
    <email>trv002@travera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbus Regional Research Institute, John B. Amos Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grayson Scott</last_name>
      <phone>706-660-6449</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.travera.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

